Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant® (baricitinib) a JAK1/2 inhibitor (I4V-MC-B010)First published 01/02/2019 Last updated 02/07/2024 EU PAS number: EUPAS25154StudyFinalised